A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This study will determine the maximum tolerated dose of RO5045337 and the optimal associated
4 weekly dosing schedule of RO5045337, administered as monotherapy in patients with
hematologic neoplasms. A first cohort of patients will receive the starting dose of
20mg/m2/day orally, once daily for 10 days in each 28 day cycle. Subsequent cohorts of
patients will receive dose escalations, and possible changes in dosing schedule, based on
tolerability and pharmacokinetic knowledge gained from prior treatment cohorts. Different
formulations of RO5045337 will be tested and the food effect evaluated. The anticipated time
on study treatment is until disease progression or intolerable toxicity.